Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials (Q36240858)

13 August 2017

0 references

1 reference

title

Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials (English)

1 reference

13 August 2017

0 references

1 reference

5

Matthew E Falagas

1 reference

13 August 2017

Sofia K Kasiakou

1

1 reference

13 August 2017

George J Sermaides

series ordinal

2

1 reference

13 August 2017

Argyris Michalopoulos

series ordinal

3

1 reference

13 August 2017

Elpidoforos S Soteriades

series ordinal

4

1 reference

13 August 2017

1 September 2005

1 reference

Lancet Infectious Diseases

13 August 2017

1 reference

13 August 2017

5

1 reference

13 August 2017

9

1 reference

13 August 2017

581-589

1 reference

Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections

13 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

A randomized study of carbenicillin plus cefamandole or tobramycin in the treatment of febrile episodes in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

A pilot study of the efficacy of constant-infusion ceftazidime in the treatment of endobronchial infections in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion of vancomycin in methicillin-resistant staphylococcus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetics and nephrotoxicity of continuous intravenous infusion of gentamicin in low birth weight infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Intermittent and continuous ceftazidime infusion for critically ill trauma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion versus intermittent administration of cefepime in patients with Gram-negative bacilli bacteraemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Treatment of gram-negative bacillary septicemia with cefoperazone.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous versus intermittent administration of ceftazidime in intensive care unit patients with nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetics and pharmacodynamics of cefepime administered by intermittent and continuous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetics and pharmacodynamics of piperacillin/tazobactam when administered by continuous infusion and intermittent dosing

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Vancomycin penetration of uninfected pleural fluid exudate after continuous or intermittent infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

"Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Cost analysis of continuous versus intermittent infusion of piperacillin-tazobactam: a time-motion study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Cost comparison of single daily i.v. doses of ceftriaxone versus continuous infusion of cefotaxime

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

The clinical efficacy of continuous-infusion flucloxacillin in serious staphylococcal sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Serum bactericidal activity of ceftazidime administered as continuous infusion of 3 g over 24 h versus intermittent bolus infusion of 2 g against Pseudomonas aeruginosa in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion ceftazidime in intensive care: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Comparison of concentrations of sulbactam-ampicillin administered by bolus injections or bolus plus continuous infusion in tissues of patients undergoing colorectal surgery

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Tissue concentrations of mezlocillin in benign hypertrophy of the prostate following intravenous bolus injection versus infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Serum bactericidal activity of ceftazidime: continuous infusion versus intermittent injections.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Integration of population pharmacokinetics, a pharmacodynamic target, and microbiologic surveillance data to generate a rational empiric dosing strategy for cefepime against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion versus intermittent administration of meropenem in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacological study of cefazolin during intermittent and continuous infusion: a crossover investigation in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Concentrations of Netilmicin in Bronchial Secretions and Serum during Intermittent vs. Continuous Infusion: A Crossover Study in Humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

A pilot study to determine the feasibility of continuous cefazolin infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Comparison of continuous with discontinuous intravenous infusion of vancomycin in severe MRSA infections

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care u

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Clinical pharmacokinetics of cefamandole and ceftazidime administered by continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Feasibility of Administering Aminoglycoside Antibiotics by Continuous Intravenous Infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetics and pharmacodynamics of aztreonam administered by continuous intravenous infusion.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetics and toxicity of continuous infusion amphotericin B in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Administration of gentamicin and ampicillin by continuous intravenous infusion to newborn infants during parenteral nutrition

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Kinetics and dose calculations of ampicillin and gentamicin given as continuous intravenous infusion during parenteral nutrition in 88 newborn infants

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Assessment of cefazolin and cefuroxime tissue penetration by using a continuous intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion of ceftazidime with an elastomeric infusion device

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion of ceftazidime in febrile neutropenic patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion of ceftazidime in the empiric treatment of febrile neutropenic children with cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Efficacy of continuous infusion of ceftazidime for patients with neutropenic fever after high-dose chemotherapy and peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Population pharmacokinetics of continuous infusion ceftazidime

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

The efficacy of continuous infusion flucloxacillin in home therapy for serious staphylococcal infections and cellulitis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetic properties and stability of continuous-infusion meropenem in adults with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Low-dose continuous-infusion ceftazidime monotherapy in low-risk febrile neutropenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Serum concentrations of cefuroxime after continuous infusion in coronary bypass graft patients

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Constant rate infusion of vancomycin in premature neonates: a new dosage schedule

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion of ceftazidime in cystic fibrosis patients during home treatment: clinical outcome, microbiology and pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Intermittent bolus dosing of ceftazidime in critically ill patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Continuous infusion of beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2805%2970218-8

7 January 2021

10.1016/S1473-3099(05)70218-8

Identifiers

DOI

1 reference

13 August 2017

1 reference